Abstract Aim-The study was designed to evaluate the long term results of intraoperative mitomycin C in patients with one recurrence of pterygium. Methods-In 45 white patients with one recurrence of pterygium the 'bare sclera technique' was performed and a sterile sponge soaked in a 0-2 mg/ml (0.02%) mitomycin C solution was placed intraoperatively on the sclera for 3 minutes. 
Methods-In 45 white patients with one recurrence of pterygium the 'bare sclera technique' was performed and a sterile sponge soaked in a 0-2 mg/ml (0.02%) mitomycin C solution was placed intraoperatively on the sclera for 3 minutes. The control group A sterile sponge (5 X 5 mm) was soaked in a sterile container containing 2 ml of a 0-02% mitomycin C solution (50 mg of 4% mitomycin C powder mixed with 10 ml of balanced salt solution). By measuring the amount of solution remaining in the container it was possible to state that after soaking in the sponge there were 0-2 ml of solution.
After the pterygium head was detached from the cornea, the soaked sponge was placed under the conjunctival flap containing the pterygium, on the sclera. After 3 minutes the sponge was removed and the site was rinsed thoroughly with 10 ml ofbalanced salt solution.
Surgery was completed with pterygium excision ('bare sclera technique'). The subconjunctival tissue superficial to the sclera was cleaned towards the insertion of the medial rectus muscle and triangular excision of the pterygium and conjunctiva, including the Informed consent for participation in the rygium was study was obtained from all patients before ig the post-their enrolment. examined n monthly, the patient Results
The follow up period was 6-54 months (mean a fibrovas-3455 (SD 13.70) months) in group 1 and previously 7-50 months (mean (1442) months) in imbus and group 2. y distance, Six recurrences (12-5%) were observed in low up was group 1 (mitomycin C treated patients) and 16 (35-6%) in group 2 (control patients). The difference between the groups was statistically significant (p=0 027). The data of life table analysis of both groups are shown in Table 2 . Survival curves are shown in Figure 1 .
In group 1 all recurrences except one occurred during the first 10 months. One recurrence was seen after 40 months of follow up.
In group 2 the highest incidence of recurrence was seen within the first 18 months. In group 1 the mean age of patients experiencing recurrence of pterygium was 30-83 (7 73) years (range 21-42 years) and in the control group it was 39-94 (9 36) years (range 21-53 years). The difference was statistically significant (p=0 047).
Complications and side effects were observed only during the first 2 weeks of follow up. In the mitomycin C treated group, the only complication was light superficial punctate keratitis. Side effects were ocular pain and photophobia in both groups (Table 3 ). After 4 weeks of follow up in one mitomycin C treated eye an area of avascularity in the site of the previous excised pterygium was detected; nevertheless no comeal changes or subjective symptoms were reported. Discussion Mitomycin C is an antibiotic antineoplastic agent, activated to an alkylating agent in tissues: it inhibits RNA DNA dependent synthesis, preventing cellular division and duplication; it has therefore been used to prevent fibroblast proliferation and scarring after filtration surgery. Since 1962 mitomycin C eyedrops have been used to prevent recurrence of pterygium after surgery, on the basis that the fibrovascular reaction in the pathogenesis of pterygium is the result of a chronic irritation. 19 Recently, the possibility of mast cells contributing to the pathogenesis of pterygia has been supposed. 20 The use of mitomycin C eyedrops after pterygium surgery seemed to be an effective and safe method to prevent recurrence of pterygium, in fact recurrence rates of between 1.4% and 13% have been published.3 5 6 21 22 Unfortunately, topical mitomycin has been reported to cause a variety of complications. Sometimes complications are very severe, such as symblepharon,6 scleral ulceration10 and necrosis,11 secondary glaucoma, and corneal perforation.'3 It is not acceptable that the surgical excision of a generally benign pathology such as pterygium should cause such serious complications.
Some authors have proposed the use of low dose mitomycin C (0-01%) after pterygium excision.23 A prospective, multicentre, randomised comparison has begun of recurrence rates after pterygium excision and intraoperative 0O04% mitomycin C for 3 minutes versus other techniques. 15 Since 1991 we have used intraoperative mitomycin C in patients with one recurrence of pterygium undergoing surgical excision. Encouraging results were shown in our preliminary study. 16 The long term results confirm the efficacy of this kind of therapy to prevent recurrence of pterygium: only six recurrences were detected in the mitomycin C treated group as against 16 recurrences in the control group (p=0 027). Life table analysis showed a success rate of 89% and 83% in the mitomycin C treated group and of 66% and 63% in the control group after 24 and 48 months of follow up, respectively (Fig 1) .
The recurrence rate in the control group is similar to those found in previous studies on bare scleral closure (24-68%).2s29
Five out of six (83-3%) and 12 out of 16 (75%) recurrences occurred within the first year in the mitomycin C treated group and control group, respectively. Our data confirm those of Hirst et a130 who affirm that a 12 month follow up is able to identify more than 97% of recurrences. In the mitomycin C treated group no patient who has not yet experienced pterygium recurrence has a follow up shorter than 1 year.
The mean age of the patients experiencing recurrence of pterygium differs significantly between the two groups (p=0 047). In the mitomycin C treated group failures were seen only in young people (mean age 30-83 (7.73); range 21-42 years). In controls recurrences were seen mostly, but not exclusively, in young people (mean age 39 94 (9 36); range 21-53 years). These data seem to show that in younger people the inhibiting effect of mitomycin C on fibroblast proliferation may be less effective in preventing fibrovascular reaction.
Although a relatively small number of patients was treated to detect complications with a very low rate, a very encouraging fact emerging from our study was the absence of the unpleasant complications and side effects reported for prolonged mitomycin C eyedrop therapy.
The exposure of the sclera for no more than 
